Poolbeg Pharma plc – Successful Artificial Intelligence led programme identifies multiple influenza drug targets
AI analysis of unique human challenge trial data provides unparalleled insights into influenza infection
Novel influenza drug targets identified faster and more cost-effectively using AI
29 June 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focusing on infectious and other prevalent diseases with a high unmet medical need, announces a significant breakthrough in its world first influenza Artificial Intelligence (‘AI’) Programme with CytoReason. Poolbeg has been working with CytoReason since March 2022.
